Repligen Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RGEN | BLFS | AVTR | AZTA | NNNN | HBIO | |
|---|---|---|---|---|---|---|
| Market cap | 10.95B | 1.89B | 10.48B | 1.65B | 193.56M | 37.51M |
| P/E (TTM) | 236.3 | 39.0 | — | — | 29.4 | — |
| Forward P/E | 65.3 | 117.0 | 17.7 | 68.4 | — | 12.8 |
| Price/book | 4.6 | 4.5 | 1.9 | 1.1 | 6.4 | 5.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +16.96% | +40.81% | +11.36% | +23.43% | −83.09% | +96.19% |
| Today | −0.79% | 0.00% | −1.15% | +0.13% | −5.36% | 0.00% |
The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.
Latest news
All RGEN news ›Novozymes A/S (CPSE: NSIS B) completed the acquisition of 77% stake in Microbiogen Pty Ltd.
Novozymes A/S signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd. on August 10, 2026. Prior to the acquisition, Novozymes A/S owns 23% stake in Microbiogen Pty Ltd. Upon... Novozymes A/S (CPSE:NSIS B) signed a…
Repligen: Abigail P. Johnson reports 13% stake
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. Stock Titan - [SCHEDULE 13G/A] REPLIGEN CORP Amended Passive Investment Disclosure Repligen: Abigail P. Johnson reports 13% stake FMR reported sole…
Repligen CEO sells 4,202 shares at $190 per share
Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO sells 4,202 shares at $190 per share Both reported sales were made under a…
Repligen completes BioLife Solutions acquisition
Repligen said BioLife will benefit from its broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships. At closing, shares issuable under BioLife options, RSUs, PSUs and RSAs…
Repligen: Olivier Loeillot proposes $238K share sale
1,333 shares vested October 2 are proposed for sale at Repligen (NASDAQ: RGEN). Stock Titan Repligen: Olivier Loeillot proposes $238K share sale The notice identifies restricted stock vesting on October 2, 2026, as the source of the shares…
Repligen CEO has 1,248 shares withheld for taxes
Repligen Corporation (RGEN) is a global life sciences company in Waltham, MA, focused on bioprocessing technologies for biological drug manufacturing. Repligen CEO has 1,248 shares withheld for taxes The withholding satisfied tax…
Recursion director proposes $242K share sale
A 50,000-share sale is proposed by director Blake C. Borgeson at Recursion (RXRX). Stock Titan Recursion director proposes $242K share sale The notice also lists three Class A sales by the director from July 7 through September 1, 2026.…
Repligen Drops 5.3% Amid Sector-Wide Selling - Alphastreet
Sector selloff drags Repligen lower. Repligen Corporation (NASDAQ:RGEN) shares tumbled 5.3% on Thursday, October 01, 2026, closing at $182.00 as a broad dow... The post Repligen Drops 5.3% Amid Sector-Wide Selling first appeared on…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net8
-
globenewswire.com1
-
marketscreener.com1
-
news.alphastreet.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.